Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 3, 2011, Pages 459-466

  Ezziddin, Samer ^a   Opitz, Martin ^a   Attassi, Mared ^b   Biermann, Kim ^a   Sabet, Amir ^a   Guhlke, Stefan ^a   Brockmann, Holger ^a   Willinek, Winfried ^a   Wardelmann, Eva ^a   Biersack, Hans Jürgen ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Department of Radiology   (Germany)

Author keywords

177Lu DOTA octreotate; Gastroenteropancreatic neuroendocrine tumours; Ki 67 index; Peptide receptor radionuclide therapy; Proliferation marker

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE LU 177; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PREDICTION; RADIOTHERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COHORT STUDIES; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953748875     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1610-2     Document Type: Article

References (18)

1. van Essen M, Krenning EP, de Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723-34. (Pubitemid 47123757)
2. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
3. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401. (Pubitemid 44451313)
4. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62. (Pubitemid 47497934)
5. Pape U, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-65.
6. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009;40:1262-8.
7. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007;14:221-32. (Pubitemid 47242624)
8. Scheidhauer K, Miederer M, Gaertner FC. PET-CT for neuroendocrine tumors and nuclear medicine therapy options (in German). Radiologe. 2009;49:217-23.
9. Knapp WH, Arnold R. Consensus protocol of the German Society of Nuclear Medicine and the section NET of the German Society of Endocrinology; workshop peptide receptor radionuclide therapy. Updated 2 December 2008. http://www.net-register.org/wDeutsch/ne-tumore/therapiemoeglichkeiten/ peptid-radiorezeptor-therapie.php
10. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009;90 (2):220-6.
11. Solcia E, Klöppel G, Sobin LH, et al. Histological typing of endocrine tumours: WHO International Histological Classification of Tumours. 2nd ed. Berlin: Springer; 2000.
12. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007;18:145-9. (Pubitemid 351378063)
13. Breeman WA, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-20. (Pubitemid 36734213)
14. Breeman WAP, van der Wansem K, Bernard BF, et al. The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30:312-5. (Pubitemid 36686853)
15. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53. (Pubitemid 23008970)
16. Pape U, Berndt U, Müller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-97.
17. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2006;47:223-33. (Pubitemid 46780886)
18. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55.